Search PubMed⌕ Search

Biomedical subjects

V P Iakovlev

Publications and source records attributed to V P Iakovlev.

At least 19 recordsLinked to original sources
PubMed1995

[Effectiveness of cefmetazole in treatment of wound infection].

The cefmetazole efficacy was studied in an open non-comparative clinical trial in the treatment of 40 patients with wound infections. The clinical results were excellent and good in 90 per cent of the cases. In 2.5 per cent of the cases the treatment failed. In 7.5 per cent of the cases the results could not be evaluated. The bacteriological efficacy of cefmetazole was equal to 80 per cent. The drug tolerance was good and only in 3 patients allergic reactions were observed. No hepatotoxic or nephrotoxic effects were recorded. The results were indicative of the advisability of the cefmetazole use in the treatment of wound infections.

Adolescent↗
PubMed1995

[Use of imipenem in the treatment of patients with surgical infection].

The efficacy of thienam, a product of Merck, Sharp and Dohme (USA) composed of imipenem and cylastatin was studied in the treatment of 52 patients with surgical infection. In 48 and 4 patients the drug was used therapeutically and prophylactically respectively. When the drug was used therapeutically the recovery and improvement were observed in 41 out of 44 patients (93.2 per cent), 4 patients being excluded from the treatment group because of adverse reactions such as hyperthermia and skin eruption. When the drug was used prophylactically the recovery and improvement were stated in all the 4 patients. The pathogens were eradicated in the wound in 40 patients (91 per cent). 114 clinical isolates were tested and the imipenem resistance was detected only in 6.5 per cent of the Staphylococcus aureus strains, in 20 per cent of the Pseudomonas aeruginosa strains and in 50 per cent of the P. mirabilis and P. vulgaris strains. All the isolates of Escherichia coli, Enterobacter, Acinetobacter and Citrobacter were susceptible or moderately susceptible to imipenem.

Adult↗
PubMed1995

[A trial of using sulperazone (cefoperazone/sulbactam) in the combined treatment of patients with a burn infection].

The experience with the use of sulperazone (a combination of cefoperazone, a 3rd generation cephalosporin, and sulbactam, a beta-lactamase inhibitor, Pfizer, USA) in the treatment of 25 patients with burns and deep burns (1 to 85 and 1 to 70 per cent of the body surface affection respectively) is described. The drug showed high clinical efficacy in the treatment of the infected burn wounds and infectious complications of the burns. Excellent and good results of the treatment were stated in 84 per cent of the patients. The extended affections and wound dissemination by multicomponent associations of polyresistant microbial strains lowered the microbiological efficacy of the treatment which amounted to 58 per cent. Rapid development of resistance to the drug in staphylococci was noted. The tolerance of sulperazone was good. The side effects were observed only in 1 patient.

Adolescent↗
PubMed1995

[Cefpiramide (Tamicin) in the treatment of purulent complications of abdominal surgery].

Fifty patients with purulent infection of the abdominal cavity were treated with cefpiramide (Lek, Slovania). The analysis of the results showed that the clinical effect was favourable in 92 percent of the patients. The bacteriological efficacy amounted to 65.2 percent. The index of the isolates susceptibility was high (72 percent at the average). The concentration of cefpiramide in the bile from the bile common duct was low (23 micrograms/ml) as a result of its partial or complete obstruction. The adverse reaction (diarrhea) was stated in 1 patient.

Abdomen↗
PubMed1995

[Effectiveness of pefloxacin in the surgical clinic].

Pefloxacin (Rhone-Poulenc, France) was used prophylactically and therapeutically in 8 and 21 surgical inpatients respectively. The majority of the Enterobacteriaceae isolates were susceptible to pefloxacin (91 to 100 per cent). The isolates of Acinetobacter spp. and Pseudomonas aeruginosa were less susceptible (77 and 33.3 per cent respectively). The isolates of Staphylococcus aureus and S. epidermidis were mainly susceptible to the drug. The high antimicrobial activity of pefloxacin used therapeutically well correlated with the favourable time course of the main disease. When pefloxacin was used prophylactically the results were positive in all the cases. The drug tolerance in the majority of the cases was good. Only 2 patients developed allergic reactions as multiple minipunctate rash. After discontinuation of the drug use and short-term course of the desensitization the clinical sings of the allergic reactions disappeared in 3 days.

Anti-Infective Agents↗
PubMed1994

[Use of a combination of cefoperazone with sulbactam for treatment of patients with wound infections].

The clinical efficacy of sulperazone (cefoperazone + sulbactam) manufactured by Pfizer (USA) was studied in the treatment of 25 patients with wound infections. By the disease severity and complications 9 patients belonged to the risk group. Insulators with abacterial media or bandages with ointments on the polyethylene glycol base and drugs stimulating reparative processes (methyl-diadioxylin, dioxyzol, gentacycol) were used for the local treatment of the wounds. The clinical efficacy was stated in 92 per cent of the cases and in 76 per cent of the cases the efficacy was bacteriological. The tolerance of sulperazon was good in all the cases. The signs of the drug intolerance or affection of the hepatic or renal function were not detected. 281 clinical isolates of the aerobic microflora were tested for their antibiotic susceptibility. The highest susceptibility to sulperazone was observed in gram-positive organisms, gram-negative bacilli (Proteus mirabilis, Escherichia coli and Klebsiella spp.) and some nonfermenting bacteria.

Adolescent↗
PubMed1994

[Use of a new drug, lomefloxacin (maxaquin), from the fluoroquinolone group in the treatment of patients with wound infection].

A clinicolaboratory study on the efficacy of lomefloxacin (maxaquin, Searle, USA) was carried out in the treatment of 31 patients with wound infections. In the complex therapy the clinical efficacy of the drug amounted to 96.7 per cent and its bacteriological activity reached 64.6 per cent. The drug tolerance in the majority of the cases was good. Only in one patient an allergic reaction in the form of multiple skin eruption on the 6th day of the treatment was recorded. One patient showed an insignificant increase in the level of alanine aminotransferase not accompanied by any signs of hepatic insufficiency.

Adolescent↗
PubMed1994

[Ofloxacin in the comprehensive therapy of complicated forms of wound infection].

A 5-year experience with the use of ofloxacin in the complex treatment of complicated wound infections showed that the drug had a broad spectrum of antimicrobial activity, was not toxic and well tolerated by the patients. The side effects were extremely rare. The antimicrobial activity of ofloxacin after its clinical use for 5 years did not practically change. The drug clinical and bacteriological efficacy in different groups of the patients ranged within 85-91 and 74-80 per cent respectively depending on the process severity. The failure of the therapy was as a rule associated with an insufficient surgical treatment of the purulent foci. It was more frequent in the patients with arteriosclerotic and diabetic gangrene of the lower extremities when due to various reasons the initial surgical operations were not radical. The short treatment courses (for not more than 5-7 days) or an early use of the drug tablets instead of the intravenous injections resulted from an insufficient experience with ofloxacin during the first years of its use. Such an unjustified tactics did not provide stable elimination of the pathogen. Our experience with ofloxacin in the treatment of various groups of patients with wound infections demonstrated that it should be considered as a reserve drug for the treatment of cases with complicated wound infections accompanied by infections of the respiratory and uropoietic organs requiring a long-term antibacterial therapy in hospitals and outpatient departments.

Combined Modality Therapy↗